Wyszukaj badanie kliniczne
101 Wyniki
Badanie kliniczne z otwartą rekrutacją
= 
; Badanie kliniczne w toku
= 
; Terminated trial = 
; Ufundowane przez członka IRDiRC = 
; MISSING CONTENT = 
Krajowe badania kliniczne
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STRONGTREAT: Ensayo clínico en Fase III, aleatorio, abierto, multicéntrico, sobre dosis múltiples o únicas de Ivermectin para el tratamiento de la estrongiloidiasis (completado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Phase III-Studie zur Einschätzung der klinischen Wirksamkeit und Sicherheit des polyclonalen Anti- Pseudomonas-Antikörpers IgY zur Vermeidung des Wiederauftretens einer Pseudomonas Aeruginosa-Infektion bei Patienten mit zystischer Fibrose
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Portatori di mutazioni precliniche provenienti da famiglie con cardiomiopatia dilatativa e ACE-inibitori (PRECARDIA)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Ensayo multicéntrico y sin enmascaramiento de la seguridad y eficacia a largo plazo de Lamazym para el tratamiento de enfermos de alfamanosidosis (Fase II) (completado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio piloto multicéntrico, de brazo único, abierto para explorar la seguridad, tolerabilidad, la farmacocinética y la eficacia de administraciones múltiples intravenosas de NI-0501, un anticuerpo monoclonal anti-interferón gamma (Anti-IFNy), en pacientes pediátricos con linfohistiocitosis hemofagocítica primaria que se ha reactivado -ES (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophy - UK (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - UK
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - SK
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio multicéntrico de seguimiento a largo plazo de pacientes con LHH que han recibido tratamiento con NI-0501, un anticuerpo monoclonal anti-interferón gamma (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MABSOT: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function - UK
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy - BE (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine offene, einarmige, multizentrische Pilot-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit der mehrfach intravenöser Gabe von NI-0501, einem monoklonalen Anti-Interferon-Gamma (Anti-IFNy) Antikörper, bei pädiatrischen Patienten mit reaktivierter primären hämophagozytischen Lymphohistiozytose (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, adaptativo y secuencial en tres partes para evaluar la seguridad, tolerabilidad y eficacia de OPN305, un anticuerpo monoclonal humanizado que bloquea el receptor de tipo Toll 2, en pacientes con trasplante renal con riesgo elevado de retraso en la función del injerto (completado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine Phase II-Studie des tumorspezifischen menschlichen Fusionsproteins monoklonalen Zytokin-Antikörpers F16IL2 in Kombination mit Paclitaxel versus Paclitaxel allein bei Patienten mit metastatischem Merkelzellkarzinom - DE -completed-
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
chILD-EU_EAA: Stop exogenous allergic alveolitis in childhood (StopEAA) - Europäische, prospektive, multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Studie zur Implementierung eines Verfahrens für die tägliche Behandlung der exogen-allergischen Alveolitis (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio de seguridad y eficacia preliminar de la infusión de células madre mesenquimales derivadas de tejido adiposo para el tratamiento de la Epidermolisis Bullosa Distrófica Recesiva (completado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio pilota, in aperto, a singolo braccio, multicentrico, per esplorare la sicurezza, tollerabilità, farmacocinetica ed efficacia di somministrazioni intravenose multiple di NI-0501, un anticorpo monoclonale anti-interferone gamma (anti-IFNgamma), in pazienti pediatrici con Linfoistiocitosi emofagocitica primaria (HLH) riattivata
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Een eerste humane en bewijs-van-concept studie om de veiligheid, tolerantie en immunologisch respons van CV-MG01, Acetylcholine Receptor Mimetic Peptides alsook van een potentieel therapeutisch vaccinatie bij patiënten met Myasthenia Gravis
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Neurosis : Etude de l'efficacité et de la tolérance du budésonide inhalé chez les nouveau-nés très grands prématurés, à risque de développer une dysplasie bronchopulmonaire - Phase III - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody (Phase II) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
INTEREST study: Estudio comparativo de fase III de grupos paralelos, aleatorizado y doble ciego sobre la eficacia y seguridad de FP-1201-lyo (interferón beta-1A recombinante humano) y placebo en el tratamiento de pacientes con síndrome de dificultad respiratoria aguda grave o moderado - ES (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DietINT: A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP08: Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MesaCapp: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome (Phase 2) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) - US
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Ensayo clínico de fase I, multicéntrico, abierto, de dosis únicas, para investigar la seguridad y tolerabilidad de una terapia génica rAAV2/5-PBGD para el tratamiento de la porfiria intermitente aguda (completado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Étude de phase 1b, randomisée, en double aveugle, contrôlée par placebo visant à évaluer l'innocuité, la tolérabilité et la pharmacocinétique du QR-010 chez des sujets atteints de fibrose kystique porteurs homozygotes de la mutation DeltaF508 - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Langzeit-Follow-up der Sicherheit und biochemischen Krankheitskontrolle von Infacort® bei Neugeborenen, Säuglingen und Kindern mit angeborener Nebennierenhyperplasie und Nebenniereninsuffizienz, die zuvor in die Infacort 003-Studie aufgenommen wurden
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
JIKI: Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Offene, langfristige Extensionsbehandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der IEDAT-02-2015-Studie teilgenommen haben -DE-
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Ensayo multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar los efectos del fosfato sódico de dexametasona intra-eritrocito en los síntomas neurológicos de pacientes con Ataxia Telangiectasia (Fase III) (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Tratamiento de extensión a largo plazo y sin enmascaramiento usando fosfato sódico de dexametasona intraeritrocitaria en pacientes con ataxia telangiectasia que participaron en el estudio IEDAT-02-2015
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio di fase IIb randomizzato, in doppio cieco, a gruppi paralleli, placebo e controllo-attivo con estensione in doppio cieco per valutare l'efficacia e la sicurezza del vamorolone in ragazzi deambulanti con distrofia muscolare di duchenne (DMD)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio randomizzato, a controllo attivo, di fase 3 per valutare l'efficacia, la sicurezza e la tollerabilità della soluzione oftalmica di 0,08% di PHMB a confronto con lo 0,02% di PHMB + 0,1% di terapia a base di propamidina in soggetti affetti da cheratite da Acanthamoeba - IT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: Étude de phase IIb randomisée, en double aveugle, en groupe parallèle, contrôlée par placebo et active avec extension en double aveugle pour évaluer l'efficacité et l'innocuité de la vamorolone chez des garçons en ambulatoire atteints de dystrophie musculaire de Duchenne
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Évaluation d'urgence du plasma de convalescence pour la maladie virale Ebola en Guinée (Ebola-Tx) (terminé)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM: Étude de phase II/III randomisée et ouverte portant sur des cellules dendritiques chargées de lysat de cellules tumorales allogéniques (PheraLys) chez des sujets atteints de mésothéliome en tant que traitement de maintenance (MesoPher) après une chimiothérapie- BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomizowane badanie III fazy, przeprowadzone metoda potrojnie slepej proby, z grupa kontrolna otrzymujaca substancje czynna, majece na celu ocene skutecznosci, bezpieczenstwa i tolerancji 0,08% roztworu biguanidu poliheksametylenowego (PHMB) do oczu w porownaniu z leczeniem 0,02% roztworem PHMB w skojarzeniu z 0,1% roztworem propamidyny u pacjentow z pelzakowatym zapaleniem rogowki
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MIROCALS : Efficacité, pharmacodynamie et sécurité de l'interleukine-2 à faible dose (ld-IL-2), en tant que stimulant des lymphocytes T régulateurs (Tregs) à visée thérapeutique anti-neuro-inflammatoire, chez des patients présentant une Sclérose Latérale Amyotrophique (SLA) nouvellement disgnostiquée : un essai randomisé, contrôlé, mené en double aveugle (Phase II) - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DENIM: Étude de phase II/III randomisée et ouverte portant sur des cellules dendritiques chargées de lysat de cellules tumorales allogéniques (PheraLys) chez des sujets atteints de mésothéliome en tant que traitement de maintenance (MesoPher) après une chimiothérapie - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomisierte, doppelblinde, Placebo-kontrollierte, Dosis-Eskalationsstudie zur Beurteilung der Sicherheit, Verträglichkeit und Pharmakokinetik von QR-010 bei CF-Patienten mit homozygoter deltaF508-Mutation
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Projet "DeSScipher" - Déchiffrer le meilleur traitement pour la sclérodermie systémique - Etude observationnelle 2: Amélioration du dysfonctionnement des mains dû à l'arthrite dans la sclérodermie systémique- BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Etude exploratoire ouverte d'évaluation de l'efficacité de QR-010 sur les différences de potentiel nasal (DDP) de patients atteints de mucoviscidose homozygote ou hétérozygote composites pour la mutation F508del (Phase I) - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Étude de Phase 1b, randomisée, en double aveugle, contrôlée par placebo, à escalade de dose pour évaluer la sécurité, la tolérance et la pharmacocinétique de QR-010 chez des sujets adultes atteints de mucoviscidose homozygote pour la mutation F508del - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous deltaF508 Cystic Fibrosis - GB
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine explorative klinische Studie von Patienten in der frühen Phase der Huntington-Krankheit zur Beurteilung der Pharmakokinetik, der pharmakodynamischen Messungen des Zieleingriffs und der Krankheitsmodulation sowie der akuten phänotypischen Effekte nach mehreren oralen Dosen von SEN0014196
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine offene Phase-3-Studie von Infacort® bei Neugeborenen, Säuglingen und Kindern unter 6 Jahren mit Nebenniereninsuffizienz
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized controlled trial (RCT) to determine the efficacy and safety of azithromycin (AZN) maintenance therapy for 6 months in subjects with PCD - A double-blind, parallel group study - GB
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GANNET53: A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomisierte kontrollierte Studie (RCT) zur Bestimmung der Wirksamkeit und Sicherheit der Erhaltungstherapie mit Azithromycin (AZN) für 6 Monate bei Patienten mit PCD - Eine doppelblinde, parallele Gruppenstudie.
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Ensayo en fase I/II de IMA970A más CV8102 tras una única infusión prevacunal de ciclofosfamida en pacientes con carcinoma hepatocelular en estadio muy inicial, inicial o intermedio que han recibido tratamientos habituales de todo tipo (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments - GB
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Essai de phase I / II portant sur IMA970A plus CV8102 après une perfusion unique de cyclophosphamide avant la vaccination chez des patients présentant un carcinome hépatocellulaire aux stades très précoce, précoce et intermédiaire après tout traitement standard - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: essai de phase II multicentrique, ouverte, randomisée, à trois bras évaluant l'innocuité et l'efficacité de Ganetespib, un inhibiteur de HSP90, en association avec le Carboplatine, suivi d'un traitement d'entretien au Niraparib versus Ganetespib plus Carboplatin chez des patientes atteintes d'un cancer ovarien sensible au platine - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ4Surfdefect: Hydroxychloroquine (HCQ) in pediatric ILD (interstitial lung disease) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HCQ-chILD-EU: Hidroxicloroquina en EPI pediátrica. START aleatorizado, controlado, de grupos paralelos, con cambio de placebo a fármaco activo, y STOP aleatorizado, controlado, de grupos paralelos, para evaluar la eficacia y seguridad de hidroxicloroquina (HCQ) -ES (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio di Fase 1b, randomizzato, in doppio cieco, controllato con placebo, a dose crescente, per valutare la sicurezza, la tollerabilità e la farmacocinetica di QR-010 in soggetti con Fibrosi Cistica con mutazione F508delta del CFTR - IT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Eine Phase-I/II-Studie mit IMA970A plus CV8102 nach einer einzigen Präimpf-Infusion von Cyclophosphamid bei Patienten mit einem sehr frühen, frühen und mittleren Stadium des hepatozellulären Karzinoms nach allen Standardbehandlungen
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GLIOMARK1: Exploratorische Phase II-Studie bei Patienten nach Behandlung eines hochgradigen Hirntumors zur Beurteilung des Stellenwerts von Tc-99m Tetrofosmin bei der Differenzierung zwischen Rezidiv und Strahlennekrose
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Treg Therapy: Therapie der Steroid-refraktären chronischen Graft-versus-Host-Erkrankung mit regulatorischen Spender-T-Zellen
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma-GB
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NICOFA: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia-GB
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapy: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children-GB
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapie: een open-label fase I / IIa-studie waarbij carbamazepine (CBZ) wordt gebruikt voor de behandeling van skeletdysplasie bij kinderen - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
NISCI: Antibodies Against Nogo-A to Enhance Plasticity, Regeneration and Functional Recovery After Spinal Cord Injury - A Multicenter International Randomized Double Blind Placebo Controlled Phase II Clinical Proof of Concept Trial - CH
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (Phase 1)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ENALONG: Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP09: Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: essai international, randomisé, contrôlé de chimiothérapies en traitement du sarcome d'Ewing récidivant et réfractaire primaire - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MCDS-Therapie: Eine offene Phase I/IIa-Studie zur Wiederverwendung von Carbamazepin (CBZ) für die Behandlung von Skelettdysplasien bei Kindern
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Open-label, langdurige extensie-studie van intra-erytrocyten Dexamethason natriumfosfaat bij patiënten met Ataxia Telangiectasia die deelnamen aan de IEDAT-02-2015-studie - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: Internationale randomisierte kontrollierte Studie zur Chemotherapie für die Behandlung von rezidivierenden und primären refraktären Ewing-Sarkomen
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
OLE-IEDAT: Offene, langfristige, verlängerte Behandlung mit Intra-Erythrozyten-Dexamethason-Natriumphosphat bei Patienten mit Ataxia Telangiectasia, die an der Studie IEDAT-02-2015 teilgenommen haben
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: essai de phase II multicentrique, ouverte, randomisée, à trois bras évaluant l'innocuité et l'efficacité de Ganetespib, un inhibiteur de HSP90, en association avec le Carboplatine, suivi d'un traitement d'entretien au Niraparib versus Ganetespib plus Carboplatin chez des patientes atteintes d'un cancer ovarien sensible au platine - FR
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PHITT: Paediatric Hepatic International Tumour Trial (Phase 3) - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TUDCA-ALS: Sicherheit und Wirksamkeit von TUDCA als Zusatztherapie bei ALS-Patienten
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio di fase 1 a dose multipla randomizzato, controllato con placebo, per valutare la sicurezza e la tollerabilità di diverse dosi di soluzione oftalmica in poliesametilene biguanide (PHMB) senza conservanti in soggetti sani
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: An international, multicentre, randomised controlled pragmatic trial of mirtazapine to alleviate breathlessness in palliative and end of life care - IE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
VISION DMD: Un estudio fase IIb aleatorizado, doble ciego, con grupo paralelo, controlado con placebo y sustancia activa con extensión doble ciego para evaluar la eficacia y seguridad de la vamorolona en niños ambulantes con distrofia muscular de Duchenne (DMD) (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: Eine internationale, multizentrische, randomisierte, kontrollierte Phase III-Studie zur Evaluation von Mirtazapin zur Linderung von Atemnot in Palliative Care
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
BETTER-B: Studio pragmatico internazionale, multicentrico, randomizzato e controllato sulla mirtazapina per alleviare la dispnea nelle cure palliative e di fine vita - IT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Decision Support System to Evaluate VENTilation in ARDS (DeVENT)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CARAMBA-1 : Eine klinische Studie der Phase I/IIa zur Beurteilung der Durchführbarkeit, Sicherheit und Antitumoraktivität von autologen SLAMF7 CAR-T-Zellen beim Multiplen Myelom
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock - AT
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUROSHOCK: Prueba del valor de una nueva estrategia y su rentabilidad para mejorar los malos resultados en el shock cardiogénico -ES
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
CARAMBA-1: Ensayo clínico fase I/IIa para evaluar la viabilidad, la seguridad y la actividad antitumoral de linfocitos autólogos CAR-T SLAMF7 en mieloma múltiple -ES
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Étude de phase III pour évaluer l'efficacité clinique et l'innocuité des anticorps anti-pseudomonas (IgY) polyclonaux aviaires dans la prévention de la récidive de l'infection à Pseudomonas aeruginosa chez des patients atteints de fibrose kystique - BE
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STOPFOP: Saracatinib-Studie zur Vorbeugung von FOP. Eine 6-monatige randomisierte, kontrollierte Doppelblindstudie mit AZD0530 im Vergleich zu Placebo, gefolgt von einer 12-monatigen Open-Label-Verlängerungsphase
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio de fase 1b, aleatorizado, doble ciego, controlado con placebo, de escalada de dosis para evaluar la seguridad, la tolerabilidad y la farmacocinética de QR-010 en sujetos con fibrosis quística homocigótica deltaF508 (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
TRACE - Trattamento di infezioni virali chemio-refrattarie dopo trapianto allogenico di cellule staminali con cellule T multispecifiche contro CMV, EBV e AdV: una sperimentazione clinica di fase III, prospettica, multicentrica
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PHITT: Internationale pädiatrische Lebertumor-Studie
European Commission
DG Research - Directorate General for Research
BELGIA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS